NEW YORK (GenomeWeb) – Transplant molecular diagnostics company CareDx today announced a supply agreement with Illumina for next-generation sequencing technologies.
Under the terms of the multiyear deal, CareDx's reference and R&D laboratories will have access to Illumina's NGS, microarray equipment, and consumables. Financial and other terms were not disclosed.
CareDx's flagship service is AlloMap Molecular Expression Testing for potential heart transplant rejection. In a statement, the company's President and CEO Peter Maag said that as CareDx expands its product pipeline from the gene expression-based AlloMap to cell-free DNA-based tests, "we believe the technology solutions from Illumina will effectively support our development and commercialization efforts."
Formerly called XDx, CareDx also recently announced the acquisition of transplant firm ImmuMetrix.